India, March 12 -- Theratechnologies Inc. (THTX) presented encouraging results from PROMISE-US, a Phase 4 study of ibalizumab in heavily treatment-experienced people with HIV, the company said in a statement on Wednesday.
The study is designed to evaluate the long-term efficacy and durability of ibalizumab in combination with other antiretroviral therapies by comparing the clinical outcomes of patients receiving ibalizumab versus those patients not receiving ibalizumab.
Results from the study showed that treatment with ibalizumab reduced HIV RNA to undetectable levels in heavily treatment-experienced patients with multidrug resistant HIV.
googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });
These data wer...